Ningbo Menovo Pharmaceutical Co.Ltd(603538) : the company has not obtained the relevant authorization for the API of namatovir
Ningbo Menovo Pharmaceutical Co.Ltd(603538) ( Ningbo Menovo Pharmaceutical Co.Ltd(603538) ) on March 15, it was announced that the holding subsidiary Zhejiang Liaoyuan mirtazapine API passed the technical review of the drug evaluation center of the State Drug Administration (hereinafter referred to as “CDE”), and the registration mark turned to “a” status on the registration information publicity platform of CDE API, pharmaceutical excipients and drug packaging materials. In addition, the company issued a change announcement that on March 15, the company disclosed the relevant matters passed the filing of the “new project with an annual output of 60 tons of anti covid-19 drug namatvir API and its key intermediates”. The company does not directly supply relevant intermediates to the patent owner and has no direct commercial cooperation with the patent owner. At present, the API of nimatovir studied by the company has not obtained relevant authorization and is only used for laboratory research and development. Nematevir (API) of the company is currently in the stage of laboratory research and development.
China Meheco Group Co.Ltd(600056) : the recent stock price increase may have exceeded the impact of relevant matters on the company’s performance
China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) on March 15, the company issued a change announcement. The recent rise of the company’s share price may have exceeded the impact of relevant matters on the company’s performance, and there may be irrational investment. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022). On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, which has not yet entered the national medical insurance and China covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
Hengbao Co.Ltd(002104) : the company currently has no business related to electronic ID card
Hengbao Co.Ltd(002104) ( Hengbao Co.Ltd(002104) ) on March 15, the company issued a change announcement. The company is concerned that the market has paid high attention to electronic ID cards and related products recently, and the company has no business related to electronic ID cards at present.
Tianqi Lithium Corporation(002466) : from January to February, the operating revenue of lithium concentrate of the company is expected to increase by about 366% year-on-year
Tianqi Lithium Corporation(002466) ( Tianqi Lithium Corporation(002466) ) announced on March 15 that from January to February, the output of lithium concentrate of the company increased by about 39% year-on-year, the sales volume increased by about 56% year-on-year, and the operating revenue of lithium concentrate is expected to increase by about 366% year-on-year. From January to February, the company expects the operating revenue of lithium compounds and their derivatives to increase by about 492% year-on-year. In 2022, the imbalance between supply and demand of lithium products has become more and more obvious due to the significant growth of demand and sales of downstream new energy vehicles. The sales price of the company’s main lithium salt products has increased rapidly, and the supply of products is in short supply.
Rongsheng Petro Chemical Co.Ltd(002493) : it is proposed to repurchase shares with RMB 1 billion to 2 billion
Rongsheng Petro Chemical Co.Ltd(002493) ( Rongsheng Petro Chemical Co.Ltd(002493) ) it was announced on March 15 that the company plans to use its own funds to buy back part of the company’s shares in the form of centralized bidding transaction for the purpose of converting the convertible corporate bonds issued by listed companies. The repurchase amount shall not be less than 1 billion yuan and not more than 2 billion yuan, and the repurchase price shall not exceed 22 yuan / share.
Weihai Guangwei Composites Co.Ltd(300699) : the shutdown had a certain adverse impact on the company’s operating performance in the first quarter
Weihai Guangwei Composites Co.Ltd(300699) ( Weihai Guangwei Composites Co.Ltd(300699) ) on March 15, it was announced that the company’s businesses suspended due to epidemic control include general new materials, composite materials, new energy materials, precision machinery and Guangsheng technology. The shutdown of some businesses and logistics of the company will delay the delivery of the company’s products, which will have a certain adverse impact on the company’s operating performance in the first quarter of 2022. According to the performance express data of 2021, the total operating revenue of the discontinued business segment (excluding Guangsheng Technology) in 2021 accounted for 51.09% of the company’s total operating revenue.
